Terms: = Cervical cancer AND WFDC2, EDDM4, HE4, WAP5, dJ461P17.6
23 results:
1. Serum expression of tumor marker CA242 in patients with different gynecological diseases.
Zhu J; Li H
Lab Med; 2023 Nov; 54(6):613-617. PubMed ID: 37035887
[TBL] [Abstract] [Full Text] [Related]
2. Detection of Circulating Tumor Cell-Related Markers in Gynecologic cancer Using Microfluidic Devices: A Pilot Study.
Law KS; Huang CE; Chen SW
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768623
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of he4 as a prognostic biomarker in uterine cervical cancer
Dubey H; Ranjan A; Durai J; Khan MA; Lakshmy R; Khurana S; Gupta S; Meena J; Ray MD; Tanwar P; Chopra A; Tiwari S
Cancer Treat Res Commun; 2023; 34():100672. PubMed ID: 36525756
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta-analysis.
Han LN; Han YW; Yan P
J Obstet Gynaecol Res; 2022 Sep; 48(9):2255-2269. PubMed ID: 35844088
[TBL] [Abstract] [Full Text] [Related]
5. Serum Human Epididymis Protein 4 as a Prognostic Marker in cervical cancer.
Hwang WY; Suh DH; Kim K; Kim YB; No JH
Cancer Control; 2022; 29():10732748221097778. PubMed ID: 35506739
[TBL] [Abstract] [Full Text] [Related]
6. Application Value of Real-Time Ultrasonic Elastograph with Serum Human Epididymis Protein 4, Interleukin-33, and Carbohydrate Antigen 153 in Diagnosis of Early cervical cancer.
Guo M; Liang L; Wu L; Xie D; Li J
J Healthc Eng; 2022; 2022():4880874. PubMed ID: 35449844
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of serum he4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.
Blackman A; Mitchell J; Rowswell-Turner R; Singh R; Kim KK; Eklund E; Skates S; Bast RC; Messerlian G; Miller MC; Moore RG
Tumour Biol; 2021; 43(1):355-365. PubMed ID: 34957977
[TBL] [Abstract] [Full Text] [Related]
8. A prediction model based on clinical and histological features for predicting recurrence in patients with stage I-II endometrial cancer after surgical treatment.
Song W; Zhao Y
Ann Diagn Pathol; 2022 Feb; 56():151861. PubMed ID: 34953233
[TBL] [Abstract] [Full Text] [Related]
9. [Clinical observational study of Nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer].
Chen J; Cao YJ; Zhu L; Zhang BL; Liu ZY; Hou HL; Chai YL; Wang P
Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(8):597-601. PubMed ID: 33663192
[No Abstract] [Full Text] [Related]
10. Circulating tumor cells in gynaecological malignancies.
Kiss I; Kolostova K; Pawlak I; Bobek V
J BUON; 2020; 25(1):40-50. PubMed ID: 32277613
[TBL] [Abstract] [Full Text] [Related]
11. Primary peritoneal serous papillary carcinoma: a case series.
Blontzos N; Vafias E; Vorgias G; Kalinoglou N; Iavazzo C
Arch Gynecol Obstet; 2019 Oct; 300(4):1023-1028. PubMed ID: 31486887
[TBL] [Abstract] [Full Text] [Related]
12. Novel Approaches to Ovarian cancer Screening.
Nebgen DR; Lu KH; Bast RC
Curr Oncol Rep; 2019 Jul; 21(8):75. PubMed ID: 31346778
[TBL] [Abstract] [Full Text] [Related]
13. Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial cancer: A Prospective Study.
Fanfani F; Restaino S; Cicogna S; Petrillo M; Montico M; Perrone E; Radillo O; De Leo R; Ceccarello M; Scambia G; Ricci G
Int J Gynecol Cancer; 2017 Jul; 27(6):1200-1205. PubMed ID: 28557834
[TBL] [Abstract] [Full Text] [Related]
14. Serum he4 is correlated to prognostic factors and survival in patients with endometrial cancer.
Stiekema A; Lok C; Korse CM; van Driel WJ; van der Noort V; Kenter GG; Van de Vijver KK
Virchows Arch; 2017 Jun; 470(6):655-664. PubMed ID: 28401338
[TBL] [Abstract] [Full Text] [Related]
15. Tissue expression of human epididymal secretory protein 4 may be useful in the differential diagnosis of uterine cervical tumors.
Diniz G; Karadeniz T; Sayhan S; Akata T; Aydiner F; Ayaz D; Solakoglu Kahraman D; Akman T
Ginekol Pol; 2017; 88(2):51-55. PubMed ID: 28326512
[TBL] [Abstract] [Full Text] [Related]
16. Further insight into prognostic factors in endometrial cancer: the new serum biomarker he4.
Capriglione S; Plotti F; Miranda A; Lopez S; Scaletta G; Moncelli M; Luvero D; De Cicco Nardone C; Terranova C; Montera R; Angioli R
Expert Rev Anticancer Ther; 2017 Jan; 17(1):9-18. PubMed ID: 27892774
[TBL] [Abstract] [Full Text] [Related]
17. Preoperative local staging of endometrial cancer: the challenge of imaging techniques and serum biomarkers.
Angioli R; Plotti F; Capriglione S; Scaletta G; Dugo N; Aloisi A; Piccolo CL; Del Vescovo R; Terranova C; Zobel BB
Arch Gynecol Obstet; 2016 Nov; 294(6):1291-1298. PubMed ID: 27535757
[TBL] [Abstract] [Full Text] [Related]
18. Detection of circulating tumour cells may add value in endometrial cancer management.
Ni T; Sun X; Shan B; Wang J; Liu Y; Gu SL; Wang YD
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():1-4. PubMed ID: 27756035
[TBL] [Abstract] [Full Text] [Related]
19. [The utility of metalloproteinases (MMPs) and their inhibitors (TIMPs) in diagnostics of gynecological malignancies].
Mieszało K; Ławicki S; Szmitkowski M
Pol Merkur Lekarski; 2016 Mar; 40(237):193-7. PubMed ID: 27088204
[TBL] [Abstract] [Full Text] [Related]
20. The role of he4 in ovarian cancer follow-up: a review.
Piovano E; Attamante L; Macchi C; Cavallero C; Romagnolo C; Maggino T; Landoni F; Gadducci A; Sartori E; Gion M; Zola P
Int J Gynecol Cancer; 2014 Oct; 24(8):1359-65. PubMed ID: 25054447
[TBL] [Abstract] [Full Text] [Related]
[Next]
